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MINIMAL RESIDUAL DISEASE (MRD) AND NEUROBLASTOMA TUMOR INI-
TIATING CELLS (NTICS) IN HEMATOPOIETIC PERIPHERAL STEM CELL
(HPBSC) COLLECTIONS FROM HIGH RISK NEUROBLASTOMA CHILDREN
WAS ASSESSED BY GENE EXPRESSION OF TH,MYCN USING QUANTITA-
TIVE REAL TIME PCR (QRT-PCR), IMMUNOPHENOTYPE ANALYSIS AND
LONG TERM CULTURE INITIATING CELL (LTC-IC)
Kletzel, M.1, Khan, S.2, Olszewski, M.2 1Northwestern University Fein-
berg School of Medicine, Chicago, IL; 2Children’s Memorial Hospital,
Chicago, IL
The presence of MRD/NTICs in autologous HPBSC collec-
tions and the high frequency of disease recurrence have great con-
cerns for transplantation. Several studies have shown that the
infusion of tumor cells with the HPBSC graft is strongly associated
with relapse. In this study we confirm the presence of MRD/
NTICs in HPBSC collected from patients who underwent autolo-
gous transplantation.
Eighteen samples from HPBSC collected from children diag-
nosed with high-risk neuroblastoma by apheresis (COBE spectra)
were deemed to be suitable for transplantation (lack expression of
Tyrosine Hydroxylase (TH) and ICC negative). At the time of col-
lection, patients were assessed to be in clinical remission (CR) or
very good partial remission (VGPR). An aliquot from each collec-
tion was assessed by various methods: gene expression of TH and
MYCN by qRT-PCR, surface marker immunophenotype using
CD56 (NCAM), GD2 and CD9 by flow cytometry and placed
on LTC-IC, after CD133 positive selection, viability and clonoge-
nicity of cells as well as gene expression (TH, MYCN) were as-
sessed at 8 weeks in culture. Undetectable gene expression (TH
or MYCN) was observed on day 0 compared to 1.8 x0 and 1.4
x-1 in negative controls vs. 2.9x6 and 9.0x2 for human neuroblas-
toma cell lines. At week 8 in LTCIC there was 6.5x3 fold increased
in expression of TH and 1.6x3 fold increased in MYCN gene ex-
pression in patient samples. while negative controls showed no in-
crease of gene expression and no change in gene expression in the
neuroblastoma cell lines. The patient samples also formed spheres,
both adherent and non-adherent that were similar morphologically
and by immunofluorescence to neurospheres generated from
neural stem cells. Generation of self-renewing cells post CD
133 selection show extensive cell proliferation with limited differ-
entiation on patient samples consistent with characteristic to
TICs. In contrast, negative controls progressed into quiescence
or apoptosis.
We conclude that HPBSC who were assessed as free of tumor at
the time of collection show the presence of MRD/TIC detected at
week 8 in LTCIC. Further studies to determine if these cells have
the ability to initiate tumors need to be performed.284
ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA
Kim, B.E., Lee, M.Y., Choi, E.S., Koh, K.N., Seo, J.J., Im, H.J. Asan
Medical Center Children’s Hospital, University of Ulsan College of Medi-
cine, Seoul, Korea
Background: Hematopoietic stem cell transplantation (HSCT)
from matched sibling donor (MSD) is a standard first-line treatment
for children with severe aplastic anemia (SAA). However, the man-
agement of SAA or very severe aplastic anemia (vSAA) lacking a suit-
able donor remains a great challenge. For those children, HSCT
using unrelated donor or mismatched related donor could be a ther-
apeutic alternative. The purpose of this study is to evaluate the out-
come in children with SAA who received HSCT from donors other
than matched sibling.
Patients andMethod: Between July 1998 and September 2011, 24
patients received HSCT from alternative donor (AD) at Asan
Medical Center Children’s Hospital. We reviewed their medical
records and analyzed their transplant-related parameters and out-
come.
Results:Of a total of 24 patients, 15 weremale and themedian age at
HSCT was 12.9 years, ranging from 3.0 to 21.7 years. Of 24, 9 had
vSAA and 2 developed SAA after liver transplantation. Seventeen pa-tients had received immunosuppressive treatment with antithymo-
globulin before HSCT, while 7 had not. The median time from
diagnosis to HSCT was 13 months, ranging from 3 to 140 months.
Donors included unrelated bone marrow (U-BM) in 3, unrelated pe-
ripheral blood (U-PB) in 8, unrelated cord blood (U-CB) in 2, re-
lated haploidentical PB (H-PB) in 8 and mismatched related donor
in 3 (1 BM, 2 PB). Of 24 patients, 23 (95.8%) achieved neutrophil
engraftment at a median of 12 days post-HSCT. One patient
(U-BM) who failed to engraft was dead despite second HSCT. Of
23 with engraftment, 2 patients (1 U-CB, 1 H-PB) died of TRM
on days +157 and +81 respectively. With a median follow up of
39.8 months, The Kaplan-Meier estimated overall survival at 3 years
was 86.0%.
Conclusion: In children with SAA, HSCT from AD including hap-
loidentical family donor could be considered as a treatment option if
the patients have no MSD. Given the limitation of this study such as
small number of patients and short follow-up period, further trial
will be necessary.285
EPSTEIN-BARR VIRUS ASSOCIATED COMPLICATIONS AND THEIR ASSO-
CIATIONWITH ANTITHYMOCYTE GLOBULIN IN PEDIATRIC ALLOGENEIC
STEM-CELL TRANSPLANTATION
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Introduction: Epstein-Barr virus (EBV) is a major concern in the
context of allogeneic hematopoietic stem-cell transplantation
(HSCT). EBV viremia, infection and post-transplant lympho-prolif-
erative disorder (PTLD) are serious complications of HSCT. Those
complications have been mainly associated with the use of antithy-
mocyte globulin (ATG) and cord blood transplantation. The aim
of this study was to assess the incidence of EBV viremia and
PTLD in pediatric patients with and without the use ATG in their
conditioning regimen.
Methods: Two-hundred and seventy-three consecutive pediatric
patients who underwent 290 allogeneic HSCT at The Hospital for
Sick Children, Toronto, Canada, between 2005 and 2010 were in-
cluded in this study. Median age at the time of transplant was 8.5
years (range, 0.2-18.0). EBV polymerase chain reaction testing was
performed weekly for the first 100 days after HSCT. A logistic re-
gression model was constructed to assess the association between
EBV viremia and the following parameters: age at time of transplant
(in years), gender, use of ATG, graft versus host disease (measured as
acute (grade 2 -4) and chronic), indication for HSCT (malignant vs.
non-malignant), PTLD, donor EBV sero-status and stem-cell
source.
Results:Of the 290 transplants performed, 127 (43.8%) used ATG.
Only 8 children experienced PTLD (2.7%), all of which also experi-
enced EBV viremia. Given this, PTLD was not included in the
models. In a uni-variable analysis the use of ATG was not found to
be associated with an increased risk of EBV viremia (p5 0.88); donor
EBV sero-positivity was found to be associated with an increased risk
for EBV viremia (p\0.001); Cord blood transplantation was associ-
ated with reduced risk for EBV viremia and PTLD (p\0.001).In the
multi- variable analysis the use of ATG was not significantly associ-
ated with EBV viremia (OR5 0.62, 95%CI:0.30-1.28) independent
of the other variables in the model. Transplantation for malignant
disease and donor seropositivity status were significantly associated
with EBV viremia independent of the other variables in the model
(OR 5 2.13, 95%CI: 1.03-4.42 and OR 5 4.50, 95%CI:
2.39-8.45, respectively).
Conclusions: EBV donor seropositivity and transplantation for
malignant disease is strongly associated with the development of
EBV viremia. EBV-viremia is very strongly associated with the de-
velopment of PTLD but the use of ATG is not associated with
EBV viremia in our experience.
